• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床实践指南中的利益冲突:一项系统评价。

Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review.

作者信息

Tabatabavakili Sahar, Khan Rishad, Scaffidi Michael A, Gimpaya Nikko, Lightfoot David, Grover Samir C

机构信息

Department of Medicine, University of Toronto, Ontario, Canada.

Division of Gastroenterology, St. Michael's Hospital, Toronto, Ontario, Canada.

出版信息

Mayo Clin Proc Innov Qual Outcomes. 2021 Jan 19;5(2):466-475. doi: 10.1016/j.mayocpiqo.2020.09.016. eCollection 2021 Apr.

DOI:10.1016/j.mayocpiqo.2020.09.016
PMID:33997642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8105509/
Abstract

OBJECTIVE

To systematically evaluate the prevalence of disclosed and undisclosed financial conflicts of interest (FCOI) among clinical practice guidelines (CPGs).

METHODS

In this systematic review, we ascertained the prevalence and types of FCOI for CPGs from January 1, 1980, to March 3, 2019. The primary outcome was the prevalence of FCOI among authors of CPGs. FCOI disclosures were compared between medical subspecialties and societies producing CPGs.

RESULTS

Among the 37 studies including 14,764 total guideline authors, 45% had at least one FCOI. The prevalence of FCOI per study ranged from 6% to 100%. More authors had FCOI involving general payments (39%) compared with research payments (29%). Oncology, neurology, and gastroenterology had the highest prevalence of FCOI compared with other medical specialties. Among the 8 studies that included the monetary values in US dollars of FCOI, average payments per author ranged from $578 to $242,300. Among the 10 studies that included data on undisclosed FCOI, 32% of authors had undisclosed industry payments.

CONCLUSION

There are numerous FCOI among authors of CPGs, many of which are undisclosed Our study found a significant difference in FCOI prevalence based on types of FCOI and CPG sponsor society. Additional research is required to quantify the implications of FCOI on clinical judgment and patient care.

摘要

目的

系统评估临床实践指南(CPG)中已披露和未披露的财务利益冲突(FCOI)的发生率。

方法

在这项系统评价中,我们确定了1980年1月1日至2019年3月3日期间CPG的FCOI发生率和类型。主要结果是CPG作者中FCOI的发生率。比较了医学亚专业和制定CPG的学会之间FCOI披露情况。

结果

在37项研究中,共有14764名指南作者,45%的作者至少存在一项FCOI。每项研究中FCOI的发生率在6%至100%之间。与研究报酬(29%)相比,涉及一般报酬的作者更多(39%)。与其他医学专业相比,肿瘤学、神经病学和胃肠病学的FCOI发生率最高。在8项包含FCOI美元货币价值的研究中,每位作者的平均报酬从578美元到242300美元不等。在10项包含未披露FCOI数据的研究中,32%的作者有未披露的行业报酬。

结论

CPG作者中存在众多FCOI,其中许多未被披露。我们的研究发现,根据FCOI类型和CPG发起学会,FCOI发生率存在显著差异。需要进一步研究来量化FCOI对临床判断和患者护理的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/8105509/da2d87575ef1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/8105509/d012255cf691/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/8105509/da2d87575ef1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/8105509/d012255cf691/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6c5/8105509/da2d87575ef1/gr2.jpg

相似文献

1
Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review.临床实践指南中的利益冲突:一项系统评价。
Mayo Clin Proc Innov Qual Outcomes. 2021 Jan 19;5(2):466-475. doi: 10.1016/j.mayocpiqo.2020.09.016. eCollection 2021 Apr.
2
Financial Conflicts of Interest in Inflammatory Bowel Disease Guidelines.炎症性肠病指南中的财务利益冲突。
Inflamm Bowel Dis. 2019 Mar 14;25(4):642-645. doi: 10.1093/ibd/izy315.
3
Undisclosed payments by pharmaceutical and medical device manufacturers to authors of endoscopy guidelines in the United States.美国制药和医疗器械制造商向内窥镜指南作者支付的未公开款项。
Gastrointest Endosc. 2020 Feb;91(2):266-273. doi: 10.1016/j.gie.2019.11.010. Epub 2019 Nov 15.
4
Industry compensation and self-reported financial conflicts of interest among authors of highly cited peripheral artery disease studies.在高引外周动脉疾病研究的作者中,行业补偿与自我报告的财务利益冲突。
J Vasc Surg. 2020 Aug;72(2):673-684. doi: 10.1016/j.jvs.2019.09.053. Epub 2020 Jan 21.
5
Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.临床实践指南中财务利益冲突的报告:对加拿大医学协会信息库指南的案例研究分析
BMC Health Serv Res. 2016 Aug 15;16(a):383. doi: 10.1186/s12913-016-1646-5.
6
Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan.制药公司向日本皮肤病学临床实践指南作者支付报酬的情况。
PLoS One. 2020 Oct 13;15(10):e0239610. doi: 10.1371/journal.pone.0239610. eCollection 2020.
7
Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019.2019 年美国国家综合癌症网络临床实践指南专家组的财务利益冲突。
Cancer. 2020 Aug 15;126(16):3742-3749. doi: 10.1002/cncr.32997. Epub 2020 Jun 4.
8
Undisclosed payments by pharmaceutical manufacturers to authors of inflammatory bowel disease guidelines in the United States.美国制药商向炎症性肠病指南作者支付的未披露款项。
Saudi J Gastroenterol. 2021 Nov-Dec;27(6):342-347. doi: 10.4103/sjg.sjg_426_21.
9
Evaluation of Financial Conflicts of Interest Among Physician-Authors of American College of Rheumatology Clinical Practice Guidelines.美国风湿病学会临床实践指南医生作者的财务利益冲突评估
Arthritis Rheumatol. 2020 Sep;72(9):1427-1434. doi: 10.1002/art.41224. Epub 2020 Jul 14.
10
Financial Conflicts of Interest Among Authors of Clinical Practice Guidelines for Routine Screening Mammography.常规乳腺 X 线筛查临床实践指南作者的财务利益冲突。
J Am Coll Radiol. 2019 Nov;16(11):1598-1603. doi: 10.1016/j.jacr.2019.05.005. Epub 2019 May 29.

引用本文的文献

1
Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy.国家综合癌症网络利益冲突财务政策的执行趋势。
JNCI Cancer Spectr. 2024 Nov 1;8(6). doi: 10.1093/jncics/pkae120.
2
Financial conflicts of interest among authors of clinical practice guideline for headache disorders in Japan.日本头痛障碍临床实践指南作者的财务利益冲突。
BMC Med Ethics. 2024 Oct 29;25(1):121. doi: 10.1186/s12910-024-01126-9.
3
Pharmaceutical industry payments to authors of neurology clinical practice guidelines in Japan: A cross-sectional study.

本文引用的文献

1
Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians.炎症性肠病生物制剂处方与制药行业向医生支付款项之间的关联。
JAMA Intern Med. 2019 Oct 1;179(10):1424-1425. doi: 10.1001/jamainternmed.2019.0999.
2
Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.评价日本肿瘤临床实践指南作者的制药公司支付情况和利益冲突披露
JAMA Netw Open. 2019 Apr 5;2(4):e192834. doi: 10.1001/jamanetworkopen.2019.2834.
3
From the American College of Chest Physicians: Guidelines on Conflict-of-Interest Management.
日本制药行业向神经病学临床实践指南作者的付款情况:一项横断面研究。
Health Sci Rep. 2024 Sep 25;7(9):e70101. doi: 10.1002/hsr2.70101. eCollection 2024 Sep.
4
Industry payments to American Society of Hematology Clinical Practice Guideline authors.制药行业向美国血液学会临床实践指南作者支付的款项。
Blood Adv. 2024 Jul 9;8(13):3549-3552. doi: 10.1182/bloodadvances.2023012527.
5
Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan.日本认证过敏专家与制药行业之间财务关系的横断面分析。
BMC Med Ethics. 2024 Feb 20;25(1):22. doi: 10.1186/s12910-024-01014-2.
6
Association between Conflicts of Interest Disclosure and Quality of Clinical Practice Guidelines in Japan: A Meta-Epidemiological Study.日本利益冲突披露与临床实践指南质量之间的关联:一项元流行病学研究。
J Pers Med. 2023 Dec 17;13(12):1722. doi: 10.3390/jpm13121722.
7
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.英国制药业向国民保健制度信托基金的付款:英国披露数据库的四年分析。
PLoS One. 2023 Nov 1;18(11):e0290022. doi: 10.1371/journal.pone.0290022. eCollection 2023.
8
How to recognize a trustworthy clinical practice guideline.如何识别值得信赖的临床实践指南。
J Anesth Analg Crit Care. 2023 Apr 28;3(1):9. doi: 10.1186/s44158-023-00094-7.
9
Transparency of clinical practice guideline funding: a cross-sectional analysis of the German AWMF registry.临床实践指南资助透明度:对德国 AWMF 注册中心的横断面分析。
BMC Med Ethics. 2023 May 19;24(1):32. doi: 10.1186/s12910-023-00913-0.
10
Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021.美国糖尿病协会《糖尿病医疗护理标准(2021年)》临床实践指南中利益冲突的财务评估及证据质量
Cureus. 2023 Mar 23;15(3):e36567. doi: 10.7759/cureus.36567. eCollection 2023 Mar.
源自美国胸科医师学会:利益冲突管理指南。
JAMA Intern Med. 2019 Apr 1;179(4):594-595. doi: 10.1001/jamainternmed.2019.0167.
4
Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories.指南制定者与制药公司之间未披露的财务关系:跨越 10 个疾病类别的横断面研究。
BMJ Open. 2019 Feb 5;9(2):e025864. doi: 10.1136/bmjopen-2018-025864.
5
Financial relationships with industry among guideline authors for the management of acute ischemic stroke.指南作者与工业界的财务关系在急性缺血性脑卒中管理中。
Am J Emerg Med. 2019 May;37(5):921-923. doi: 10.1016/j.ajem.2019.01.037. Epub 2019 Jan 24.
6
Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines.行业向国家综合癌症网络指南作者提供的建议和支付的证据。
Oncologist. 2019 Apr;24(4):498-504. doi: 10.1634/theoncologist.2017-0655. Epub 2018 Nov 20.
7
Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications.高收益药物相关临床指南作者的财务利益冲突发生率。
JAMA Intern Med. 2018 Dec 1;178(12):1712-1715. doi: 10.1001/jamainternmed.2018.5106.
8
Evaluation of Industry Relationships Among Authors of Clinical Practice Guidelines in Gastroenterology.评价胃肠病学临床实践指南作者的行业关系。
JAMA Intern Med. 2018 Dec 1;178(12):1711-1712. doi: 10.1001/jamainternmed.2018.4730.
9
Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.英国制药公司向医疗保健专业人员披露款项:对英国制药工业协会披露数据库 2015 年和 2016 年队列的分析。
BMJ Open. 2018 Oct 21;8(10):e023094. doi: 10.1136/bmjopen-2018-023094.
10
Financial Conflicts of Interest in Inflammatory Bowel Disease Guidelines.炎症性肠病指南中的财务利益冲突。
Inflamm Bowel Dis. 2019 Mar 14;25(4):642-645. doi: 10.1093/ibd/izy315.